Results 181 to 190 of about 68,398 (251)

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series. [PDF]

Front Immunol
Berkovich R, Calkwood J, Crayton H, Erwin A, Faissner S, Gold R, Katz J, Leekoff M.   +7 more
europepmc   +1 more source

Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. [PDF]

Front Immunol, 2022
Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, Fernández-Román IM, López-Barba J, de la Cruz-Merino L, Rodríguez-Baño J, Palacios-Baena ZR.   +7 more
europepmc   +1 more source

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia. [PDF]

J Hematol Oncol, 2022
Guisado-Vasco P, Carralón-González MM, Aguareles-Gorines J, Martí-Ballesteros EM, Sánchez-Manzano MD, Carnevali-Ruiz D, García-Coca M, Barrena-Puertas R, de Viedma RG, Luque-Pinilla JM, Sotres-Fernandez G, Fernández-Sousa JM, Luepke-Estefan XE, López-Martín JA, Jimeno JM.   +14 more
europepmc   +1 more source

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Zhang Y, Ren Y, Zhuang J, Yuan L, Wang Z, Zhang X, Wang W, Cheng Z, Cheng L, Li J, Liu P.   +10 more
europepmc   +1 more source

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma. [PDF]

Ann Hematol
Yang P, Li CY, Liu SZ, Wang J, Chen YT, Zhang WL, Jing HM.   +6 more
europepmc   +1 more source

Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis. [PDF]

Front Immunol
Deng M, Zeng F, Kong Z, Li T.
europepmc   +1 more source

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. [PDF]

Mult Scler, 2021
Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, Shubin R, Wray S, Weiss MS, Bosco JA, Power SA, Mok K, Inglese M.   +12 more
europepmc   +1 more source

Echovirus serotype 11 induced sepsis in a young female patient with multiple sclerosis treated with anti-CD20 monoclonal antibody ocrelizumab. [PDF]

Infection
Starosta AD, Ehler J, Löffler B, Tannapfel A, Zipprich A, Reuken PA, Stallmach A.   +6 more
europepmc   +1 more source

First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders. [PDF]

CNS Neurosci Ther
Yu H, Chen Y, Qi Y, Yang H, Cao G, Yang W, Li S, Yang X, Wang H, Zhang J, Chen X.   +10 more
europepmc   +1 more source

Establishment of C₂₀Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells. [PDF]

Oncol Lett, 2020
Furusawa Y, Kaneko MK, Kato Y.
europepmc   +1 more source